1064 related articles for article (PubMed ID: 25607927)
21. Increased plasma lipid levels exacerbate muscle pathology in the mdx mouse model of Duchenne muscular dystrophy.
Milad N; White Z; Tehrani AY; Sellers S; Rossi FMV; Bernatchez P
Skelet Muscle; 2017 Sep; 7(1):19. PubMed ID: 28899419
[TBL] [Abstract][Full Text] [Related]
22. Protein-Anchoring Therapy of Biglycan for Mdx Mouse Model of Duchenne Muscular Dystrophy.
Ito M; Ehara Y; Li J; Inada K; Ohno K
Hum Gene Ther; 2017 May; 28(5):428-436. PubMed ID: 27485975
[TBL] [Abstract][Full Text] [Related]
23. Lack of the serum- and glucocorticoid-inducible kinase SGK1 improves muscle force characteristics and attenuates fibrosis in dystrophic mdx mouse muscle.
Steinberger M; Föller M; Vogelgesang S; Krautwald M; Landsberger M; Winkler CK; Kasch J; Füchtbauer EM; Kuhl D; Voelkl J; Lang F; Brinkmeier H
Pflugers Arch; 2015 Sep; 467(9):1965-74. PubMed ID: 25394886
[TBL] [Abstract][Full Text] [Related]
24. Temporal gene expression profiling of dystrophin-deficient (mdx) mouse diaphragm identifies conserved and muscle group-specific mechanisms in the pathogenesis of muscular dystrophy.
Porter JD; Merriam AP; Leahy P; Gong B; Feuerman J; Cheng G; Khanna S
Hum Mol Genet; 2004 Feb; 13(3):257-69. PubMed ID: 14681298
[TBL] [Abstract][Full Text] [Related]
25. Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.
Janssen PM; Murray JD; Schill KE; Rastogi N; Schultz EJ; Tran T; Raman SV; Rafael-Fortney JA
PLoS One; 2014; 9(2):e88360. PubMed ID: 24551095
[TBL] [Abstract][Full Text] [Related]
26. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.
Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A
Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083
[TBL] [Abstract][Full Text] [Related]
27. The role of Notch signaling in muscle progenitor cell depletion and the rapid onset of histopathology in muscular dystrophy.
Mu X; Tang Y; Lu A; Takayama K; Usas A; Wang B; Weiss K; Huard J
Hum Mol Genet; 2015 May; 24(10):2923-37. PubMed ID: 25678553
[TBL] [Abstract][Full Text] [Related]
28. Identification of FHL1 as a therapeutic target for Duchenne muscular dystrophy.
D'Arcy CE; Feeney SJ; McLean CA; Gehrig SM; Lynch GS; Smith JE; Cowling BS; Mitchell CA; McGrath MJ
Hum Mol Genet; 2014 Feb; 23(3):618-36. PubMed ID: 24087791
[TBL] [Abstract][Full Text] [Related]
29. miR-146a deficiency does not aggravate muscular dystrophy in mdx mice.
Bronisz-Budzyńska I; Chwalenia K; Mucha O; Podkalicka P; Karolina-Bukowska-Strakova ; Józkowicz A; Łoboda A; Kozakowska M; Dulak J
Skelet Muscle; 2019 Aug; 9(1):22. PubMed ID: 31412923
[TBL] [Abstract][Full Text] [Related]
30. Diaphragm muscle fibrosis involves changes in collagen organization with mechanical implications in Duchenne muscular dystrophy.
Sahani R; Wallace CH; Jones BK; Blemker SS
J Appl Physiol (1985); 2022 Mar; 132(3):653-672. PubMed ID: 35050792
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological activation of PPARbeta/delta stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice.
Miura P; Chakkalakal JV; Boudreault L; Bélanger G; Hébert RL; Renaud JM; Jasmin BJ
Hum Mol Genet; 2009 Dec; 18(23):4640-9. PubMed ID: 19744959
[TBL] [Abstract][Full Text] [Related]
32. Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy.
Percival JM; Whitehead NP; Adams ME; Adamo CM; Beavo JA; Froehner SC
J Pathol; 2012 Sep; 228(1):77-87. PubMed ID: 22653783
[TBL] [Abstract][Full Text] [Related]
33. Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice.
van Putten M; Hulsker M; Young C; Nadarajah VD; Heemskerk H; van der Weerd L; 't Hoen PA; van Ommen GJ; Aartsma-Rus AM
FASEB J; 2013 Jun; 27(6):2484-95. PubMed ID: 23460734
[TBL] [Abstract][Full Text] [Related]
34. The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies.
Banks GB; Chamberlain JS
Curr Top Dev Biol; 2008; 84():431-53. PubMed ID: 19186250
[TBL] [Abstract][Full Text] [Related]
35. [Study on the gene knockout model mice of Duchenne muscular dystrophy].
Chen S; Zhang C; Liu X; Gao L; Zhang W; Huang W; Lu X; Wang Z
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Apr; 34(2):210-3. PubMed ID: 12947691
[TBL] [Abstract][Full Text] [Related]
36. Improvement in survival and muscle function in an mdx/utrn(-/-) double mutant mouse using a human retinal dystrophin transgene.
Gaedigk R; Law DJ; Fitzgerald-Gustafson KM; McNulty SG; Nsumu NN; Modrcin AC; Rinaldi RJ; Pinson D; Fowler SC; Bilgen M; Burns J; Hauschka SD; White RA
Neuromuscul Disord; 2006 Mar; 16(3):192-203. PubMed ID: 16487708
[TBL] [Abstract][Full Text] [Related]
37. Changes in calsequestrin, TNF-α, TGF-β and MyoD levels during the progression of skeletal muscle dystrophy in mdx mice: a comparative analysis of the quadriceps, diaphragm and intrinsic laryngeal muscles.
Barros Maranhão J; de Oliveira Moreira D; Maurício AF; de Carvalho SC; Ferretti R; Pereira JA; Santo Neto H; Marques MJ
Int J Exp Pathol; 2015 Oct; 96(5):285-93. PubMed ID: 26515458
[TBL] [Abstract][Full Text] [Related]
38. Cathelicidin-related antimicrobial peptide mediates skeletal muscle degeneration caused by injury and Duchenne muscular dystrophy in mice.
Choi MC; Jo J; Lee M; Park J; Yao TP; Park Y
J Cachexia Sarcopenia Muscle; 2022 Dec; 13(6):3091-3105. PubMed ID: 36059045
[TBL] [Abstract][Full Text] [Related]
39. Increasing muscle contractility through low-frequency stimulation alters tibial bone geometry and reduces bone strength in
Chan AS; Hardee JP; Blank M; Cho EH; McGregor NE; Sims NA; Lynch GS
J Appl Physiol (1985); 2023 Jul; 135(1):77-87. PubMed ID: 37262103
[TBL] [Abstract][Full Text] [Related]
40. Iron overload and impaired iron handling contribute to the dystrophic pathology in models of Duchenne muscular dystrophy.
Alves FM; Kysenius K; Caldow MK; Hardee JP; Chung JD; Trieu J; Hare DJ; Crouch PJ; Ayton S; Bush AI; Lynch GS; Koopman R
J Cachexia Sarcopenia Muscle; 2022 Jun; 13(3):1541-1553. PubMed ID: 35249268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
